Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack

Boston Scientific has downgraded its outlook for 2026, citing the impact of a recent cybersecurity breach on its operations. The company's shares fell 2.1% before trading began on September 8, as it announced it no longer anticipates meeting previously issued sales and profit forecasts for the third quarter and full year of 2026.

The unauthorized access to Boston Scientific's IT systems, detected on August 25, caused a network outage that disrupted manufacturing, order processing, and shipment, according to a regulatory filing. While the company has made progress in restoring affected systems, with major distribution centers now handling orders at or above normal levels, and sterilization facilities operational, the full financial impact of the incident remains uncertain.

Boston Scientific expects to recoup some lost revenue as it ramps up operations, fulfills customer orders, and reduces backlogs, but the complete effect of the cyberattack on its financials is unclear. The company plans to provide further details on the operational and financial consequences of the incident when it releases its third-quarter results on October 28.

This latest cyberattack follows a growing number of security breaches in the healthcare sector, including those affecting Abbott Laboratories, Stryker, Medtronic, Clover Health, and Novo Nordisk.